ArticleMultiple sclerosis and related disorders2012
The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics.
Article in Multiple sclerosis and related disorders, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 7 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.Health technology assessment (Winchester, England) · 2026Pooled it
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Polygenicity of Comorbid Depression in Multiple Sclerosis.Neurology · 2023Pooled it
- Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023Pooled it
- Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- Early complement genes are associated with visual system degeneration in multiple sclerosis.Brain : a journal of neurology · 2019Pooled it
- Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.The Cochrane database of systematic reviews · 2016Pooled it
- Trial
- Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Trial
- Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.Neurology · 2020Trial
- Are multi-contrast magnetic resonance images necessary for segmenting multiple sclerosis brains? A large cohort study based on deep learning.Magnetic resonance imaging · 2020Trial
- Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.Multiple sclerosis and related disorders · 2017Trial
- Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.Multiple sclerosis (Houndmills, Basingstoke, England) · 2017Trial
- Trial
- Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study.Human brain mapping · 2015Trial
- Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.Multiple sclerosis and related disorders · 2015Trial
- Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.BMC neurology · 2014Trial
- Randomized study combining interferon and glatiramer acetate in multiple sclerosis.Annals of neurology · 2013Trial
- Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.Annals of neurology · 2025Article
- Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosis.Annals of clinical and translational neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundInterferon-β1a (IFNB) and glatiramer acetate (GA) are distinct therapies which are both partially effective for relapsing MS. It is not known if combining the two treatments would be more effective.
objectiveTo review the rationale, design, and baseline characteristics of the CombiRx study of combined treatment with IFNB and GA.
methodsThe key inclusion criteria included a diagnosis of relapsing MS, at least 2 episodes of MS activity in the previous 3 years, expanded disability status scale of 0 to 5.5, and no prior treatment with either IFNB or GA. Subjects were randomized to IFNB+GA, IFNB monotherapy, or GA monotherapy in a 2:1:1 ratio.
resultsFrom 2005 to 2009, we enrolled 1008 subjects. The participants were 72.4% female and 87.6% Caucasian with a mean age of 37.7 years. The median duration of symptoms was 2 years at entry into the study, and the mean EDSS was 2.1. On the baseline MRI, the mean total lesion load was 12.2 ml, and 40% of the participants had enhancing lesions.
conclusionWe have recruited a population of patients with clinical and MRI characteristics typical for early MS. The study results will aid in deciding on the optimum early treatment. This trial should serve as a model for future studies of combination therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.